ホジキンリンパ腫：2029年までの疫学予測

ホジキンリンパ腫 (HL) はリンパ系に影響を与える癌性の状態であり、子供と大人の双方で発生します。 HLは、リンパ球と呼ばれる白血球の異常な成長から始まり、リンパ系を超えて広がり、体の免疫系を損なう稀な疾患です。 HLは、cHL (古典的ホジキンリンパ腫) とNLPHL (結節性リンパ球優位型ホジキンリンパ腫) の2つの主要なグループに分類されます。 cHLはさらにサブタイプ、すなわち結節硬化型、混合細胞型、リンパ球豊富型、およびリンパ球減少型に分類されます。古典的HLは最も頻繁に発生するHLであり、HL症例のほぼ95％がcHLタイプに属しています。2019年には、主要8市場において24,885件のHLの発生事例が診断されました。これは、0.99％の年間成長率（AGR）で、2029年までに27,134件に増加すると予想されます。

当レポートでは、世界の主要8市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本、中国都市部) におけるホジキンリンパ腫 (HL) の動向について調査し、セグメント別 (疾患の分類、性別、年齢、癌の病期など) による10年間の疫学予測を提供しています。

第1章 目次

第2章 ホジキンリンパ腫：エグゼクティブサマリー

• 触媒
• 関連レポート
• 今後のレポート

第3章 疫学

• 疾患の背景
• リスク要因と併存疾患
• 世界のおよび歴史的傾向
• 予測調査手法
  • ソース
  • 使用されていないソース
  • 予測の前提条件と手法
• ホジキンリンパ腫の疫学予測
  • ホジキンリンパ腫の診断件数
  • 古典的ホジキンリンパ腫の診断件数
  • 古典的ホジキンリンパ腫の診断件数：年齢別
  • 古典的ホジキンリンパ腫の診断件数：性別
  • 古典的ホジキンリンパ腫の診断件数：癌の病期別
  • 古典的ホジキンリンパ腫の診断件数：癌のサブタイプ別
  • 古典的ホジキンリンパ腫の5ヵ年の有病件数
  • 結節性リンパ球優位型ホジキンリンパ腫の診断件数
• 議論
  • 疫学予測の考察
  • COVID-19の影響
  • 分析の制限事項
  • 分析の強み

第4章 付録

List of Tables

List of Tables

• Table 1: Summary of Newly Added Data Types and Countries
• Table 2: Summary of Updated Data Types
• Table 3: HL Cancer Stages
• Table 4: Risk Factors and Comorbidities for HL

List of Figures

List of Figures

• Figure 1: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, 2019 and 2029
• Figure 2: 8MM, Diagnosed Incidence Rates of cHL, All Ages, Both Sexes, Cases per 100,000 Population, 2009-2029
• Figure 3: Sources Used for Diagnosed Incident Cases of HL, cHL, and NLPHL
• Figure 4: Sources Used for Diagnosed Incident Cases of cHL by Stage
• Figure 5: Sources Used for Diagnosed Incident Cases of cHL Subtypes
• Figure 6: Sources Used for Five-Year Diagnosed Prevalent Cases of cHL
• Figure 7: 8MM, Diagnosed Incident Cases of HL, Both Sexes, All Ages, N, 2019
• Figure 8: 8MM, Diagnosed Incident Cases of cHL, Both Sexes, All Ages, N, 2019
• Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of cHL, Both Sexes, N, 2019
• Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of cHL, All Ages, N, 2019
• Figure 11: 8MM, Diagnosed Incident Cases of cHL by Cancer Stage at Diagnosis, Both Sexes, All Ages, N, 2019
• Figure 12: 8MM, Diagnosed Incident Cases of cHL by Cancer Subtypes, Both Sexes, All Ages, N, 2019
• Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of cHL, Both Sexes, All Ages, N, 2019 and 2029
• Figure 14: 8MM, Diagnosed Incident Cases of NLPHL, Both Sexes, All Ages, N, 2019

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HL incidence. GlobalData epidemiologists applied country-specific incidence rates of HL, wherever available, to each country's population to obtain the number of estimated diagnosed incident cases.

HL is a cancerous condition that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts with abnormal growth of the white blood cells, called lymphocytes, and then spreads beyond the lymphatic system and impairs the body's immune system. HL is classified into two main groups-cHL and NLPHL. cHL is further divided into subtypes, namely nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. The classical form is the most frequently occurring HL, with almost 95% of HL cases belonging to the cHL type.

The following data describes epidemiology of HL cases. In 2019, the 8MM had 24,885 diagnosed incident cases of HL. This is expected to increase to 27,134 diagnosed incident cases by 2029, at an Annual Growth Rate (AGR) of 0.90%. This increase is partly attributed to the moderately rising trend in incidence in the 8MM, combined with underlying demographic changes in the respective markets. In the 8MM, the diagnosed incident cases of cHL will increase from 22,815 cases in 2019 to 24,820 cases in 2029, at an AGR of 0.88%, and the diagnosed incident cases of NLPHL will increase from 2,074 cases in 2019 to 2,314 cases in 2029, at an AGR of 1.18%. The development of more effective therapies, particularly for elderly patients, would improve survival from HL.

Scope

• Hodgkin Lymphoma (HL) Epidemiology Report provides an overview of the risk factors and global trends of Hodgkin Lymphoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
• This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of HL, classical HL (cHL), Nodular Lymphocyte Predominant HL (NLPHL); diagnosed incident cases of cHL segmented by sex and age, for all ages in 10-year age groups beginning at 0 years and ending at ≥85 years; diagnosed five-year prevalent cases cHL; diagnosed incident cases of cHL by cancer staging (stage I -IV); and diagnosed incident cases of cHL by subtypes (nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted).
• The HL Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

• The HL Epidemiology series will allow you to:
• Develop business strategies by understanding the trends shaping and driving the global HL, cHL, and NLPHL market.
• Quantify patient populations in the global HL market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the cHL cancer stages that present the best opportunities for cHL therapeutics in each of the markets covered.
• Understand magnitude of cHL market by subtypes.

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Hodgkin Lymphoma: Executive Summary

• 2.1 Catalyst
• 2.2 Related Reports
• 2.3 Upcoming Reports

3 Epidemiology

• 3.1 Disease Background
• 3.2 Risk Factors and Comorbidities
• 3.3 Global and Historical Trends
• 3.4 Forecast Methodology
  • 3.4.1 Sources
  • 3.4.2 Sources Not Used
  • 3.4.3 Forecast Assumptions and Methods
• 3.5 Epidemiological Forecast for Hodgkin Lymphoma (2019-2029)
  • 3.5.1 Diagnosed Incident Cases of Hodgkin Lymphoma
  • 3.5.2 Diagnosed Incident Cases of Classical Hodgkin Lymphoma
  • 3.5.3 Age-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
  • 3.5.4 Sex-Specific Diagnosed Incident Cases of Classical Hodgkin Lymphoma
  • 3.5.5 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Stage
  • 3.5.6 Diagnosed Incident Cases of Classical Hodgkin Lymphoma by Cancer Subtypes
  • 3.5.7 Five-Year Diagnosed Prevalent Cases of Classical Hodgkin Lymphoma
  • 3.5.8 Diagnosed Incident Cases of Nodular Lymphocyte Predominant Hodgkin Lymphoma
• 3.6 Discussion
  • 3.6.1 Epidemiological Forecast Insight
  • 3.6.2 COVID-19 Impact
  • 3.6.3 Limitations of Analysis
  • 3.6.4 Strengths of Analysis

4 Appendix

• 4.1 Bibliography
• 4.2 About the Authors
  • 4.2.1 Epidemiologist
  • 4.2.2 Reviewers
  • 4.2.3 Global Director of Therapy Analysis and Epidemiology
  • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
• 4.3 About GlobalData
• 4.4 Contact Us
• 4.5 Disclaimer